Search

Your search keyword '"Hubiche T"' showing total 327 results
Start Over Author "Hubiche T"
327 results on '"Hubiche T"'

1. Diffuse skin findings secondary to lymph node tularemia in a patient with chronic rheumatoid arthritis on methotrexate

Author

Kandemir, S, Dezoteux, F, Loiez, C, Hubiche, T, Laurent, S, and Darras, S

Subjects
adenopathy, case report, immunosuppressed, skin, tularemia
Abstract

Tularemia has many atypical presentations which can represent a diagnostic challenge. The history is essential in the investigation of this disease. Bite-induced primary skin lesions should be distinguished from the infrequent immune-mediated secondary skin lesions. Herein, we present an atypical pseudovesicular rash secondary to Francisella tularensis.

Published
2023

5. Localized acne induced by radiation therapy

Author

Hubiche, T and Sibaud, V

Subjects
ionizing radiation, comedones, acne, pustules, comedo reaction
Abstract

The appearance of localized acne or comedo reaction during or shortly after radiotherapy is an unusual adverse event, but one that is probably underestimated. It can manifest as an inflammatory (papules, pustules, nodules), comedonal (open and closed comedones, Favre-Racouchot-like syndrome), or mixed presentation. We report two new cases of radiation-induced acne with different clinical aspects and discuss the main known features of this adverse event.

Published
2014

6. Manifestations cutanées atypiques lors de l’apparition de l’arthrite juvénile idiopathique de forme systémique et difficultés de traitement : une étude rétrospective multicentrique

Author

Eveillard, L.A., primary, Quartier, P., additional, Ouldali, N., additional, Bader-Meunier, B., additional, Bourrat, E., additional, Aeschlimann, F., additional, Ballot, C., additional, Bouric, P., additional, Desdoits, A., additional, Dumaine, C., additional, Galeotti, C., additional, Hentgen, V., additional, Lefevre-Utile, A., additional, Chausset, A., additional, Hubiche, T., additional, Kupfer-Bessaguet, I., additional, Leclerq-Mercier, S., additional, Mallet, S., additional, Melki, I., additional, Merlin, E., additional, Miquel, J., additional, Piram, M., additional, Talmud, D., additional, Garcelon, N., additional, Vinit, C., additional, Welfringer, A., additional, and Meinzer, U., additional

Published
2022
Full Text
View/download PDF

12. Multifocal Tuberculosis in 2021: What Place for Genetics?

Author

Gourdan, P., primary, Colanic, I., additional, Blanc, S., additional, Fina, A., additional, Baque-Juston, M., additional, Solla, F., additional, Giordano, A., additional, Hubiche, T., additional, Rohrlich, P., additional, Barlogis, V., additional, Bustamante, J., additional, Boisson-Dupuis, S., additional, and Giovannini-Chami, L., additional

Published
2022
Full Text
View/download PDF

13. Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicentre retrospective cohort in daily practice

Author

Lasek, A., Bellon, N., Mallet, S., Puzenat, E., Bursztejn, A.C., Abasq, C., Mazereeuw‐hautier, J, Chiaverini, C., Hubiche, T., Raison Peyron, N., Du Thanh, A., Barbarot, Sébastien, Aubert, H., Reguiai, Z., Droitcourt, C., Fievet, C., Bellissen, A., Bachelerie, M., Nosbaum, A., Leymarie, A., Armingaud, P., Masson Regnault, M., Mahé, E., Groupe Hospitalier de l'Institut Catholique de Lille (GHICL), Université catholique de Lille (UCL), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de Dermatologie et Allergologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire de Nice (CHU Nice), Hôpital Archet 2 [Nice] (CHU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Physiopathologie des Adaptations Nutritionnelles (PhAN), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Lille, CHU Marseille, CHU Clermont-Ferrand, Université de Lyon, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Régional d'Orléans (CHRO), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre Hospitalier Victor Dupouy, and None

Subjects
atopic dermatitis, Dermatology, Conjunctivitis, Severity of Illness Index, Dermatitis, Atopic, Immunoglobulin A, Cohort Studies, Infectious Diseases, Treatment Outcome, children, dupilumab, Humans, daily practice, Child, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology, Retrospective Studies
Abstract

International audience; Background: Dupilumab is the first biotherapy available for the treatment of moderate-to-severe childhood atopic dermatitis (AD).Objective: The aim of this study was to evaluate the effectiveness and safety of dupilumab in daily practice.Methods: Patients aged 6-11, who had received a first dose of dupilumab, were included in this multicentre retrospective cohort study. The primary endpoint was change in SCORAD after 3 months of treatment. Secondary endpoints were change in IGA score at 3 months, proportion of patients with SCORAD50 and SCORAD75, description of adverse events and proportion of children in our cohort who would be excluded from pivotal phase 3 clinical trial.Results: Eighty patients were included. After 3 months of treatment, there was a significant decrease in SCORAD (mean: 21.8 ± 13.8 vs 53.9 ± 18.5; P < 0.0001) and IGA (1.3 ± 0.8 vs 3.5 ± 0.7; P < 0.0001). Conjunctivitis was observed in 11.3% (n = 9/80); three patients experienced dupilumab facial redness (DFR); 17.5% (n = 14/80) reported injection site reactions; 6.3% (n = 5/80) discontinued treatment. 61.2% (n = 49/80) children were ineligible in the phase 3 trial.Limitations: There is no control group. Because it was a real life study based on information from patient medical records in a French multicentre cohort, we cannot rule out the presence of reporting bias generated by the use of patient reported characteristics and missing information.Conclusion: These real-life data confirm the efficacy and safety of dupilumab in children with moderate to severe AD extended to dyshidrosis and atopic prurigo, but it also revealed a lower frequency of DFR and conjunctivitis. However, administration in injectable form may be a barrier in this age group.

Published
2022

16. Œdème douloureux et purpura rhumatoïde de l’enfant (PRODE)

Author

Benhayoun, C., Hubiche, T., and Chiaverini, C.

Abstract

Le purpura rhumatoïde (PR) est la vascularite la plus fréquente chez l’enfant. C’est une vascularite des petits vaisseaux qui touche principalement la peau, le tube digestif, les articulations et les reins. Le diagnostic est le plus souvent aisé devant l’association classique d’un purpura infiltré des membres inférieurs, d’arthralgies et de douleurs abdominales, mais des formes atypiques existent, retardant le diagnostic et parfois même la mise en place d’une thérapeutique adaptée. Nous présentons une série de cas multicentriques d’un symptôme peu rapporté, les œdèmes hyperalgiques, principalement du dos, évocateurs de purpura rhumatoïde. Il s’agit ici des premiers cas d’une étude observationnelle multicentrique qui précise les caractéristiques cliniques, évolutives et paracliniques d’œdèmes douloureux apparus au cours d’un purpura rhumatoïde de l’enfant et leur traitement.

Published
2024
Full Text
View/download PDF

17. Anti-TNFα dans la dermatose neutrophilique pédiatrique résistante aux corticostéroïdes

Author

Chêne, L., Hubiche, T., De Guillebon, J.M., Severino Freire, M., Bourrat, E., Barberot, S., and Chiaverini, C.

Abstract

Les dermatoses neutrophiliques (DN) sont rares chez l’enfant. La présentation dermatologique est généralement similaire à celle de l’adulte, mais avec une fréquence plus élevée de manifestations extra-cutanées. Le traitement est mal codifié, en particulier dans les cas de résistance ou de dépendance aux stéroïdes. Nous présentons 4 cas de DN pédiatrique sévère ayant nécessité un traitement anti-TNFα.

Published
2024
Full Text
View/download PDF

18. Effets à long terme du sirolimus sur les malformations vasculaires à flux lent: données réelles de l’étude observationnelle multicentrique française SIROLO

Author

Maillet, C., Boccara, O., Mallet, S., Bessis, D., Léauté-Labrèze, C., Prey, S., Guibaud, L., Bisdorff, A., Dompmartin, A., Mazereeuw-Hautier, J., Chiaverini, C., Hubiche, T., Bertille, B., Chopinet, C., Bursztejn, A.C., Aubert, H., Severino Freire, M., Leducq, S., Tardieu, M., Joly, A., Boulouis, G., Le Touze, A., Paré, A., Tavernier, E., and Maruani, A.

Abstract

Le sirolimus est un traitement des malformations vasculaires de bas débit (MVBD). L’étude SIROLO visait à évaluer les effets à long terme et la prise en charge en vraie vie du sirolimus oral pour les MVBD en examinant les données de 15 centres français.

Published
2024
Full Text
View/download PDF

19. Efficacité du dupilumab sur le prurit dans l’épidermolyse bulleuse dystrophique : données en vie réelle d’une étude rétrospective bicentrique

Author

Kandemir, S., Chiaverini, C., Hubiche, T., Bourrat, E., and Hovnanian, A.

Abstract

L’épidermolyse bulleuse dystrophique est une génodermatose caractérisée par une fragilité cutanéomuqueuse. Le prurit est un symptôme majeur avec des conséquences délétères sur l’état cutané, la qualité de vie et le sommeil, pour lequel il n’existe actuellement aucune thérapie efficace et validée. L’épidermolyse bulleuse dystrophique pruriginosa est un sous-type modéré, caractérisé par un prurit majeur pour lequel le dupilumab semble être très efficace. Cette étude a évalué l’efficacité du dupilumab sur le prurit et la qualité du sommeil chez des patients atteints de différents sous-types d’épidermolyse bulleuse dystrophique.

Published
2024
Full Text
View/download PDF

23. Étude de la tolérance et de l’efficacité du dupilumab dans les dermatoses inflammatoires associées à un déficit immunitaire primitif : cohorte rétrospective de 38 patients

Author

Guillemin, C., Levy, R., Barbarot, S., Bellon, N., Bourrat, E., Chiaverini, C., Cougoul, P., Du Thanh, A., Ebbo, M., Fahri, J., Gourguechon, C., Guiddir, T., Herber, M., Hubiche, T., Jachiet, M., Lipsker, D., Mallet, S., Raison-Peyron, N., Tauber, M., Neven, B., Mahlaoui, N., Bodemer, C., and Polivka, L.

Published
2023
Full Text
View/download PDF

25. Gale commune de l’enfant et de l’adulte : comparaison de la perméthrine topique à 5 % à l’ivermectine orale 200 μg/kg administrées à 2 reprises. Essai contrôlé randomisé en cluster avec évaluateur en insu

Author

Boralevi, F., Simon, G., Miraglia, J., Bernigaud, C., Brun, J., Perrot, J.L., Goujon, E., Phan, A., Herissé, A.L., Maruani, A., Vanhaecke, C., Couty, E., Mallet, S., Abasq-Thomas, C., Hubiche, T., Brenaut, E., Caux, F., Beneton, N., Aubert, H., Bourrat, E., Adamski, H., Miquel, J., Loget, J., Janela, R., Couzan, C., Eyraud, A., Marti, A., Duong, T.A., Bonniaud, B., Barbarot, S., Dinulescu, M., Lebidre, E., Leducq, S., Monestier, S., Seneschal, J., Etienne, M., Huet, F., Delion, F., Morice-Picard, F., Léauté-Labrèze, C., Capelli, A., Giraudeau, B., and Chosidow, O.

Published
2023
Full Text
View/download PDF

27. Skin manifestations of COVID-19 in children:Part 1

Author

Andina, D., Belloni-Fortina, A., Bodemer, C., Bonifazi, E., Chiriac, A., Colmenero, I., Diociaiuti, A., El-Hachem, M., Fertitta, L., van Gysel, D., Hernández-Martín, A., Hubiche, T., Luca, C., Martos-Cabrera, L., Maruani, A., Mazzotta, F., Akkaya, A. D., Casals, M., Ferrando, J., Grimalt, R., Grozdev, I., Kinsler, V., Morren, M. A., Munisami, M., Nanda, A., Novoa, M. P., Ott, H., Pasmans, S., Salavastru, C., Zawar, V., Torrelo, A., Andina, D., Belloni-Fortina, A., Bodemer, C., Bonifazi, E., Chiriac, A., Colmenero, I., Diociaiuti, A., El-Hachem, M., Fertitta, L., van Gysel, D., Hernández-Martín, A., Hubiche, T., Luca, C., Martos-Cabrera, L., Maruani, A., Mazzotta, F., Akkaya, A. D., Casals, M., Ferrando, J., Grimalt, R., Grozdev, I., Kinsler, V., Morren, M. A., Munisami, M., Nanda, A., Novoa, M. P., Ott, H., Pasmans, S., Salavastru, C., Zawar, V., and Torrelo, A.

Abstract

The current COVID-19 pandemic is caused by the SARS-CoV-2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS-CoV-2 infection in children differ from those in adults as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID-19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discuss one of the first and most widespread cutaneous manifestation of COVID-19, chilblain-like lesions. In Part 2, we review other manifestations, including erythema multiforme, urticaria and Kawasaki disease-like inflammatory multisystemic syndrome, while in Part 3, we discuss the histological findings of COVID-19 manifestations, and the testing and management of infected children, for both COVID-19 and any other pre-existing conditions.

Published
2021

29. Intertrigo péri-alaire de l’enfant et de l’adolescent : étude descriptive prospective multicentrique d’une nouvelle entité clinique (Étude TRIGONASO)

Author

Sanchez, A., primary, Mahé, E., additional, Miquel, J., additional, Abasq, C., additional, Phan, A., additional, Mazereeuw-Hautier, J., additional, Lemille, J., additional, Maruani, A., additional, Bonniaud, B., additional, Plantin, P., additional, Mallet, S., additional, Martin, H., additional, Hubiche, T., additional, Chiaverini, C., additional, and Lacour, J.-P., additional

Published
2020
Full Text
View/download PDF

30. Acrosyndromes aigus pédiatriques au cours de l’épidémie de COVID-19 : étude des caractéristiques de la cellule familiale

Author

Hubiche, T., primary, Phan, A., additional, Leducq, S., additional, Rapp, J., additional, Fertitta, L., additional, Aubert, H., additional, Barbarot, S., additional, Chiaverini, C., additional, Giraudeau, B., additional, Labarelle, A., additional, Mc Craig, C., additional, Martin, L., additional, Monitor, L., additional, Nicol, I., additional, Piram, M., additional, Bissuel, M., additional, Bellissen, A., additional, Lasek, A., additional, Mallet, S., additional, Vabres, P., additional, and Maruani, A., additional

Published
2020
Full Text
View/download PDF

33. Malformations capillaires multiples : intérêt du dépistage systématique des malformations artérioveineuses du système nerveux central

Author

Boccara, O., primary, Mazereeuw, J., additional, Martin, L., additional, Bessis, D., additional, Hubiche, T., additional, Chiaverini, C., additional, Dompmartin, A., additional, Mallet, S., additional, Miquel, J., additional, Aubert, H., additional, Puzenat, E., additional, Abasq, C., additional, Gusdorf, L., additional, Hadj-Rabia, S., additional, and Maruani, A., additional

Published
2020
Full Text
View/download PDF

34. Pseudo-engelures associées à la Covid-19 : interféronopathie de type 1 et microvasculopathie

Author

Hubiche, T., primary, Cardot-Leccia, N., additional, Le Duff, F., additional, Seitz-Polski, B., additional, Giordana, P., additional, Chiaverini, C., additional, Giordanengo, V., additional, Gonfrier, G., additional, Raimondi, V., additional, Bausset, O., additional, Adjtoutah, Z., additional, Garnier, M., additional, Burel-Vandenbos, F., additional, Dadone-Montaudié, B., additional, Fassbender, V., additional, Palladini, A., additional, Courjon, J., additional, Mondain, V., additional, Contenti, J., additional, Dellamonica, J., additional, Leftheriotis, G., additional, and Passeron, T., additional

Published
2020
Full Text
View/download PDF

35. Increased incidence of cutaneous Staphylococcusaureusinfections after the 2010 floods in the Var department of France: Rumour or reality?

Author

Suarez-Diaz, E., Hubiche, T., and Del Giudice, P.

Abstract

Natural disasters are typically associated with the emergence of infectious diseases. On 15 June 2010, severe storms caused flooding in the Var department (France). A rumour about increased risk of Staphylococcusaureusskin infections after bathing in the sea began to circulate on Internet a few days after the floods. The aim of this study was to compare the rumour with the true incidence of cases of infection.

Published
2022
Full Text
View/download PDF

39. Une syphilis « précoce »

Author

Sanchez, A., primary, Del Giudice, P., additional, Peneau, A., additional, Grange, P., additional, Dupin, N., additional, and Hubiche, T., additional

Published
2020
Full Text
View/download PDF

40. Testing a possible new way to diagnose scabies

Author

Delaunay, P., primary, Hérisé, A.L., additional, Hasseine, L., additional, Chiaverini, C., additional, Tran, A., additional, Mary, C., additional, Del Giudice, P., additional, Marty, P., additional, Akhoundi, M., additional, and Hubiche, T., additional

Published
2020
Full Text
View/download PDF

41. 测试一种可能的新的疥疮诊断方法

Author

Delaunay, P., primary, Hérisé, A.L., additional, Hasseine, L., additional, Chiaverini, C., additional, Tran, A., additional, Mary, C., additional, Del Giudice, P., additional, Marty, P., additional, Akhoundi, M., additional, and Hubiche, T., additional

Published
2020
Full Text
View/download PDF

42. Profil du télédermatologue en France en 2019

Author

Bataille, M., primary, Mahé, E., additional, Vuong, V., additional, Dompmartin, A., additional, Richard, M.-A., additional, Debarbieux, S., additional, Doutre, M.-S., additional, Friedel, J., additional, Ottavy, F., additional, Jouan, N., additional, Pépin, E., additional, Pistorius, V., additional, Perier, M., additional, Brenaut, E., additional, Kottler, D., additional, Hirsch, G., additional, Hubiche, T., additional, Morand, J.-J., additional, Ollivaud, L., additional, Gallais, V., additional, Gautier, M.-S., additional, Carvalho, P., additional, and Duong, T.-A., additional

Published
2019
Full Text
View/download PDF

50. Doubles variants somatiques non-alléliques activateurs d’oncogènes dans les malformations vasculaires cutanées en mosaïque

Author

Vabres, P., Hubiche, T., Mallet, S., Maruani, A., Boccara, O., Dadone-Montaudié, B., Martel, J., Bonniaud, B., Faivre, L., and Kuentz, P.

Abstract

Contrairement aux multiples variants somatiques observés dans les cancers, les variants somatiques activateurs dans les malformations vasculaires (MV) cutanées en mosaïque impliquent généralement un seul oncogène. Cependant, des doubles variants non alléliques ont récemment été rapportés dans des anomalies en mosaïque, mais leur fréquence reste mal connue et leur pathogénicité incertaine.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results